Inhibrx Biosciences (INBX) Projected to Post Earnings on Monday

Inhibrx Biosciences (NASDAQ:INBX) is expected to be posting its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect Inhibrx Biosciences to post earnings of ($2.08) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 20, 2026 at 5:00 PM ET.

Inhibrx Biosciences Price Performance

INBX stock opened at $69.18 on Monday. The business’s 50-day moving average is $77.08 and its two-hundred day moving average is $63.07. The company has a debt-to-equity ratio of 2.71, a current ratio of 4.49 and a quick ratio of 4.49. The firm has a market capitalization of $1.01 billion, a P/E ratio of -6.90 and a beta of 1.50. Inhibrx Biosciences has a 1 year low of $10.81 and a 1 year high of $94.57.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Citigroup restated a “market perform” rating on shares of Inhibrx Biosciences in a research note on Wednesday, November 19th. Weiss Ratings reiterated a “sell (d)” rating on shares of Inhibrx Biosciences in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Institutional Trading of Inhibrx Biosciences

A number of institutional investors have recently bought and sold shares of the business. Morgan Stanley boosted its position in shares of Inhibrx Biosciences by 163.7% during the 4th quarter. Morgan Stanley now owns 1,167,728 shares of the company’s stock worth $92,251,000 after acquiring an additional 724,872 shares in the last quarter. Sofinnova Investments Inc. raised its position in shares of Inhibrx Biosciences by 1.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 708,678 shares of the company’s stock worth $10,113,000 after acquiring an additional 10,762 shares in the last quarter. State Street Corp raised its position in shares of Inhibrx Biosciences by 83.9% during the 4th quarter. State Street Corp now owns 374,961 shares of the company’s stock worth $29,622,000 after acquiring an additional 171,038 shares in the last quarter. Millennium Management LLC lifted its stake in Inhibrx Biosciences by 8.0% during the third quarter. Millennium Management LLC now owns 297,820 shares of the company’s stock worth $10,031,000 after purchasing an additional 22,042 shares during the last quarter. Finally, Caligan Partners LP purchased a new stake in Inhibrx Biosciences during the third quarter worth approximately $7,961,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.